Article in The Journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors at 3 institutions in 1 country.
Jeffrey B DribanJ.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston; jeffrey.driban@tufts.edu.ORCID 0000-0001-6098-4273
Matthew S HarkeyM.S. Harkey, PhD, Postdoctoral Research Fellow, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston, and Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester.ORCID 0000-0002-3480-3173
Lori Lyn PriceL.L. Price, MAS, Statistician, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts.
Grace H LoG.H. Lo, MD, Assistant Professor, Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, and Section of Immunology, Allergy, and Rheumatology Baylor College of Medicine, Houston, Texas, USA.
Timothy E McAlindonJ.B. Driban, PhD, ATC, CSCS, Associate Professor, T.E. McAlindon, MD, Chief of Rheumatology, Allergy, and Immunology, Division of Rheumatology, Allergy, and Immunology, Tufts Medical Center, Boston.
Tufts Medical Center · USMichael E. DeBakey VA Medical Center · USTufts University · US
Funding
Tufts Clinical and Translational Science Institute (Pilot Supplement)UL1TR002544 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2018 to 2022
$50.2M
DATA COORDINATING CENTER FOR THE OSTEOARTHRITIS INITIATIVEN01AR22258 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEVITT, MICHAEL · 2007 to 2011
$13.5M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVEN01AR22259 · NIDCD · UNIVERSITY OF MARYLAND BALTIMORE · PI HOCHBERG, MARC C. · 2007 to 2011
$7.8M
Clinical Centers for the Osteoarthritis Initiative^Rhode IslandN01AR22262 · NIAMS · MEMORIAL HOSPITAL OF RHODE ISLAND · PI EATON, CHARLES B. · 2007 to 2010
$6.8M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVEN01AR22261 · NIAMS · OHIO STATE UNIVERSITY RESEARCH FDN · PI JACKSON, REBECCA · 2007 to 2011
$6.2M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVEN01AR22260 · NIDCD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2007 to 2010
$6.1M
University of Massachusetts Center for Clinical and Translational ScienceTL1TR001454 · NCATS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LEWIS, BRIAN C · 2015 to 2024
$3.6M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-264022259-264022259N01AR022259 · NIAMS · UNIVERSITY OF MARYLAND AT BALT · PI HOCHBERG, MARC C. · 2002 to 2006
–
CLINICAL CENTER FOR THE OSTEOARTHRITIS-264022262-264022262N01AR022262 · NIAMS · THE MEMORIAL HOSPITAL · PI ASSAF, ANNLOUISE R. · 2002 to 2006
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-N01AR22261N01AR022261 · NIAMS · OHIO STATE UNIVERSITY RESEARCH · PI JACKSON, REBECCA · 2002 to 2006
–
NEW PHARMACOLOGY ASPECTS RELATED TO CARBONIC ANHYDRASER01HL022258 · NHLBI · UNIVERSITY OF FLORIDA · PI MAREN, THOMAS H · 1985 to 1986
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-N01AR22260N01AR022260 · NIAMS · UNIVERSITY OF PITTSBURGH · PI KWOH, KENT · 2002 to 2006
objectiveWe assessed if the inverse Osteoarthritis Research Society International (OARSI) and Outcome Measures in Rheumatology (OMERACT) criteria relate to concurrent radiographic knee osteoarthritis (KOA) progression and decline in walking speed, as well as future knee replacement.
methodsWe conducted knee-based analyses of data from the Osteoarthritis Initiative. All knees had symptomatic OA: at least doubtful radiographic KOA (Kellgren-Lawrence grade ≥ 1) and knee pain ≥ 10/100 (Western Ontario and McMaster Universities Osteoarthritis Index pain) at the 12-month visit. The inverse of the OARSI-OMERACT responder criteria depended on knee pain and function, and global assessment of knee impact. We used generalized linear mixed models to assess the relationship of the inverse OARSI-OMERACT criteria over 2 years (i.e., 12-month and 36-month visits) with worsening radiographic severity (any increase in Kellgren-Lawrence grade from 12 months to 36 months) and decline in self-selected 20-m walking speed of ≥ 0.1m/s (from 12 months to 36 months). We used a Cox model to assess time to knee replacement during the 6 years after the 36-month visit as an outcome.
resultsAmong the 1746 analyzed, 19% met the inverse OARSI-OMERACT criteria. Meeting the inverse OARSI-OMERACT criteria was associated with almost double the odds of experiencing concurrent worsening in radiographic KOA severity (OR 1.89, 95% CI 1.32-2.70) or decline in walking speed (OR 1.82, 95% CI 1.37-2.40). A knee meeting the inverse OARSI-OMERACT criteria was more likely to receive a knee replacement after the 36-month visit (23%) compared with a nonresponder (10%; HR 2.54, 95% CI 1.89-3.41).
conclusionThe inverse OARSI-OMERACT criteria for worsening among people with KOA had good construct validity in relation to clinically relevant outcomes.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Inverse OARSI-OMERACT Criteria Is a Valid Indicator of the Clinical Worsening of Knee Osteoarthritis: Data From the Osteoarthritis Initiative. · full record | OpenQuestion